Anti-VEGFR-2 drugs, including the monoclonal antibody ramucirumab and a variety of small-molecule tyrosine kinase inhibitors, remain solely used for the systemic treatment of malignant tumors (e.g., gastric and gastroesophageal adenocarcinoma in the second-line setting) [46], and are only in early trials for eventual ophthalmologic applications [47,48]. This evidence concerns the gene KDR and cancer.